GlassScriptPhysician profile
Dallas Cottam
NPI 1043423056
$214.71
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2021: $12.76 · 2022: $96.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69.90 | 2022 | |
| Cepheid | $45.66 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $36.08 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.41 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dallas Cottam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.